Aster DM Healthcare is currently trading at Rs. 158.65, up by 0.55 points or 0.35% from its previous closing of Rs. 158.10 on the BSE.
The scrip opened at Rs. 158.85 and has touched a high and low of Rs. 159.90 and Rs. 153.40 respectively. So far 2055 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 169.00 on 21-Jan-2019 and a 52 week low of Rs. 109.70 on 07-Aug-2019.
Last one week high and low of the scrip stood at Rs. 162.75 and Rs. 153.40 respectively. The current market cap of the company is Rs. 7750.19 crore.
The promoters holding in the company stood at 37.80%, while Institutions and Non-Institutions held 17.63% and 44.57% respectively.
Aster DM Healthcare is eyeing 25 percent of its total revenues from India operations in the next 3-5 years as it undertakes a slew of initiatives to scale up its business in the country. At present, around 85 percent of company’s business comes from GCC region and around 15 percent from India operations.
For this, the company plans to increase the capacity utilisation of its facilities in India from the current 60 percent to up to 75 percent which is optimum. It will make significant improvements in the revenues. In addition to this, the company is also entering into the diagnostics segment in India.
Aster DM Healthcare operates as a healthcare company in the Middle East, India, and the Far East. It operates hospitals and clinics, pharmacies, diagnostic centers, educational institutions, and healthcare management and healthcare support systems.
| Company Name | CMP |
|---|---|
| Apollo Hospital Ent. | 7699.05 |
| Max Healthcare Inst | 1006.90 |
| Narayana Hrudayalay | 1825.55 |
| Aster DM Healthcare | 688.30 |
| Global Health | 1089.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: